GERON CORP
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
GERN$0.97-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| (In thousands) | |||
| Cash flows from operating activities: | |||
| Net loss | $(184,127) | $(141,901) | $(116,112) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 442 | 288 | 215 |
| Accretion and amortization on investments, net | (11,150) | (965) | 1,424 |
| Amortization of debt issuance costs/debt discount | 1,088 | 1,327 | 893 |
| Net gain on exchange and sales of equity investment | — | — | (1,233) |
| Stock-based compensation for services by non-employees | 828 | 264 | 91 |
| Stock-based compensation for employees and directors | 18,526 | 8,001 | 8,080 |
| Amortization of right-of-use assets | 591 | 580 | 568 |
| Changes in assets and liabilities: | |||
| Interest and other receivables | 1,490 | (1,381) | (1,041) |
| Prepaid and other current assets | (886) | (2,630) | 1,317 |
| Deposit and other assets | 692 | (594) | (3,807) |
| Accounts payable | (4,029) | 3,503 | (232) |
| Accrued compensation and benefits | 2,224 | 3,435 | (119) |
| Accrued liabilities | 7,208 | 3,266 | 14,909 |
| Operating lease liabilities | (640) | (572) | (509) |
| Net cash used in operating activities | (167,743) | (127,379) | (95,556) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (830) | (431) | (207) |
| Purchases of marketable securities | (475,594) | (258,007) | (177,434) |
| Proceeds from maturities of marketable securities | 296,102 | 320,505 | 247,994 |
| Proceeds from sales of equity investment | — | — | 1,594 |
| Net cash provided by (used in) investing activities | (180,322) | 62,067 | 71,947 |
| Cash flows from financing activities: | |||
| Proceeds from issuances of common stock from equity plans | 13,072 | 2,185 | 797 |
| Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs | 213,337 | 69,916 | — |
| Proceeds from issuances of common stock from at market offerings, net of paid issuance costs | — | — | 20,385 |
| Proceeds from exercise of warrants | 105,912 | 15,163 | 2,479 |
| Proceeds from debt financing, net of paid debt issuance costs and debt discounts | 29,700 | — | 24,895 |
| Net cash provided by financing activities | 362,021 | 87,264 | 48,556 |
| Net effect of exchange rates on cash, cash equivalents and restricted cash | (27) | 22 | — |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,929 | 21,974 | 24,947 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 57,209 | 35,235 | 10,288 |
| Cash, cash equivalents and restricted cash at the end of the period | $71,138 | $57,209 | $35,235 |
NOTES TO FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.